{
"id":"mk19_bb_on_s7",
"subspecialtyId":"on",
"title":"Neuroendocrine Tumors",
"jsonContent":{
"type":"section",
"id":"mk19_bb_on_s7",
"title":{
"__html":"Neuroendocrine Tumors"
},
"titleNode":{
"type":"section-title",
"hlId":"6f40fc",
"children":[
"Neuroendocrine Tumors"
]
},
"children":[
{
"type":"section",
"id":"mk19_bb_on_s7_1",
"title":{
"__html":"Diagnosis"
},
"titleNode":{
"type":"section-title",
"hlId":"523223",
"children":[
"Diagnosis"
]
},
"children":[
{
"type":"p",
"hlId":"682046",
"children":[
{
"type":"no-wrap",
"children":[
{
"type":"abbreviation",
"title":"neuroendocrine tumor",
"children":[
"NET"
]
},
"s"
]
},
" arising from the endocrine cells of the pancreas are called pancreatic NETs, whereas those arising from the digestive tract are called gastrointestinal NETs."
]
},
{
"type":"p",
"hlId":"98a2eb",
"children":[
"Most NETs are hormonally nonfunctioning, but about 25% manifest a hormone. Gastrointestinal NETs can produce serotonin, which may cause diarrhea and facial flushing, and gastrin, which may cause peptic ulcer disease."
]
},
{
"type":"p",
"hlId":"fe2a68",
"children":[
"Pancreatic NETs may produce insulin, gastrin, glucagon, somatostatin, or vasoactive intestinal peptide, with resulting hormonal syndromes based on the type of hormone elaborated. This tumor may be part of the multiple endocrine neoplasia type 1 (MEN1) syndrome (primary hyperparathyroidism, pituitary tumors, enteropancreatic tumors)."
]
},
{
"type":"p",
"hlId":"d8d194",
"children":[
"Nonfunctioning tumors may be asymptomatic and develop metastatic disease many years before diagnosis."
]
}
]
},
{
"type":"section",
"id":"mk19_bb_on_s7_2",
"title":{
"__html":"Testing"
},
"titleNode":{
"type":"section-title",
"hlId":"fa6a5a",
"children":[
"Testing"
]
},
"children":[
{
"type":"p",
"hlId":"a1e113",
"children":[
"Initial evaluation of NETs includes CT imaging. Imaging with radiolabeled somatostatin analogues or MRI is used in tumor localization."
]
}
]
},
{
"type":"section",
"id":"mk19_bb_on_s7_3",
"title":{
"__html":"Treatment"
},
"titleNode":{
"type":"section-title",
"hlId":"4c4ac0",
"children":[
"Treatment"
]
},
"children":[
{
"type":"p",
"hlId":"2dfe60",
"children":[
"Most NETs are indolent and can be followed until symptomatic. Surgery can be used to remove localized tumors. Hormonally active tumors with somatostatin receptors may be treated with the somatostatin analogue octreotide or lanreotide."
]
}
]
}
]
},
"tablesContent":{
}
}